The Athenex team includes a deep bench of professionals with experience in pharmaceutical research, product development, manufacturing and quality assurance.
Michael has contributed substantially to the development of Athenex’s clinical pipeline, operations, and platform technologies, including the Optimized PhotoAffinity Labelling (OPAL) platform technology which is a keystone to Athenex’s drug discovery efforts today. As the Company’s primary chemist since 2008, he has made significant contributions to Athenex’s clinical pipeline through hands-on research and management of IND-enabling studies including many aspects of drug substance, product, and process development.
Prior to joining Athenex, Michael completed a postdoctoral position at Scripps Florida where he focused on the drug discovery of kinase inhibitors, which resulted in several patent applications and publications. Michael obtained his PhD from SUNY University at Buffalo, and his multi-disciplinary PhD thesis on the “Thermodynamics of Molecular Recognition” contained breakthrough findings for the biotechnology industry.
Rob, an analytical chemist, has implemented effective quality management systems for over 20 years. Prior to joining Athenex, in his role as Global Quality Leader for Thermo Fisher Scientific, Rob oversaw 13 regulated manufacturing sites around the world. He has extensive experience in Quality Assurance and Validation, having led large teams in pharma, biotech and medical device companies, including Bristol Myers Squibb and Fujisawa, and assuming roles in R&D, Project Management, QC and QA/QC. Rob is proficient in execution of compliance to GMP 21 CFR 210/211/820 and has experience with lean manufacturing, six sigma training, and risk management. Early in his career, Rob focused on method development and quality control testing for biomedical companies. He received a Bachelors in Chemistry and a Master in Analytical Chemistry from Buffalo State College, State University of New York.
In his current role at Athenex, Rob leads the development of manufacturing operations for both proprietary and 503b products. His team has developed and implemented injectable products for the 503b business and is preparing one of the Athenex sites to produce the proprietary ointment product.
John has over 20 years of global human resources and operations management experience in the healthcare industry with a concentration in developing human resource competencies in high growth businesses. In his role at Athenex, John is responsible for providing overall leadership to the company’s global human resources organization and programs, including leadership and organization development, performance management, training, compensation and benefits, staffing, employee relations, HRIS, and affirmative action/diversity.
Prior to joining Athenex, John held several leadership roles including Vice President, Human Resources for Sagent Pharmaceuticals, Vice President of Human Resources at Pfingsten Partners, Global Human Resource, Executive Vice President for Stericycle, and varying positions of management responsibility in Human Resources at Baxter Healthcare.
John attended Loyola University of Chicago and holds a B.A. in Organizational Communications, as well as several executive educational certificates in operations from Kellogg School of Management.
Li has extensive experience in financial capital markets including financial analysis, planning, accounting and auditing, asset management and risk management for both public and private companies. Prior to joining Athenex, Li worked in the audit and assurance services for PricewaterhouseCoopers in New York City, leading audit engagements in the capital market area. Her clients included key US banks, investment companies, the depository trust company and large insurance companies. She has a proven record of implementing procedures to promote financial excellence, optimizing company structure while serving as business partners to operational managers to improve financial results. Li graduated with an MBA in professional accounting from Rutgers University and she is a certified public accountant in New York State. She received her BA in English Language and Literature from Shanghai International Studies University.
Jacqueline joined Athenex in 2017 to support the company’s strategic and operational objectives, including in respect of capital raising, business development, investor relations and project management. Jacqueline is also the CFO of Axis Therapeutics, a majority-owned subsidiary of Athenex principally engaged in the development of T cell therapies. Prior to joining Athenex, Jacqueline was with Credit Suisse’s Investment Banking and Capital Markets division in Hong Kong, advising clients from various sectors spanning life sciences, general industrials, internet and others. Over the past 10 years, Jacqueline has developed deep experience through the execution of capital markets, mergers and acquisitions, strategic partnership and other financing transactions, including the initial public offering of Athenex. Jacqueline graduated with a B.S. in Economics from The Wharton School, University of Pennsylvania.
Beny has over 8 years of Corporate Finance experience in the Clinical Research industry in Latin America. He oversaw the regional expansion in CIDAL from 2011-2015 gaining considerable experience in the regions local markets. Beny was an integral part of the APA process between Athenex and CIDAL. In his role as Regional CFO, Beny looks after finance and accounting matters for the Latin America and UK regions.
Beny received his MBA from Francisco Marroquin University in Guatemala with a minor in entrepreneurship from Tulane University. Beny also spent 9 months at National Taiwan Normal University studying Mandarin.
Xiaodong has served as General Manager of Chongqing Taihao Pharmaceutical since August 2012. He participated in the establishment, development, and restructuring of the Chongqing Taihao Pharmaceutical from 2004 to 2012, and served as Vice President of Supply, Marketing and Sales. Xiaodong served as Manager of Administration, Marketing and Sales of Chongqing United Pharmaceutical, later merged to Holley Pharmaceutical (SSE: 600607) from 1997 to 2004. He has over 18 years experience in pharmaceutical and chemistry.
Xiaodong has his MBA from Chongqing University in China.
Xiaoli has served as Chongqing Taihao Pharmaceutical’s Vice General Manager of administration and Chief Financial Officer since August 2012. Xiaoli served in Chongqing Xiyong Microelectronics Industrial Park, a Chongqing Municipal key state-owned enterprises, engaged in the establishment of finance department from 2011 to 2012. She served as Audit Manager, CFO of Chongqing Holley Pharmaceutical, which is a listed pharmaceutical company in China (SSE: 600607) and has more than 20 domestic and overseas subsidiaries, from August 2004 to October 2011. Xiaoli served as Audit, Project Evaluation Manager of Chongqing Kanghua Accounting Firm from January 2000 to July 2004.
Xiaoli held various certificates, such as CPA, Certified Real Estate Appraiser in China. She also has her MBA from Chongqing University.
Edward has over 15 years of experience in accounting, auditing, financial management, corporate finance and risk management. Prior to joining Athenex, Edward was the Financial Controller of Hong Kong listed companies. Prior to that, Edward was a Finance Manager of a US listed energy company and an audit manager of KPMG Hong Kong.
Edward graduated with a Bachelor of Business Administration major in professional accounting and he is also a member of The Hong Kong Institute of Certified Public Accountant.